Literature DB >> 20086148

Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.

Donna M MacCallum1, Alix Coste, Françoise Ischer, Mette D Jacobsen, Frank C Odds, Dominique Sanglard.   

Abstract

Principal mechanisms of resistance to azole antifungals include the upregulation of multidrug transporters and the modification of the target enzyme, a cytochrome P450 (Erg11) involved in the 14alpha-demethylation of ergosterol. These mechanisms are often combined in azole-resistant Candida albicans isolates recovered from patients. However, the precise contributions of individual mechanisms to C. albicans resistance to specific azoles have been difficult to establish because of the technical difficulties in the genetic manipulation of this diploid species. Recent advances have made genetic manipulations easier, and we therefore undertook the genetic dissection of resistance mechanisms in an azole-resistant clinical isolate. This isolate (DSY296) upregulates the multidrug transporter genes CDR1 and CDR2 and has acquired a G464S substitution in both ERG11 alleles. In DSY296, inactivation of TAC1, a transcription factor containing a gain-of-function mutation, followed by sequential replacement of ERG11 mutant alleles with wild-type alleles, restored azole susceptibility to the levels measured for a parent azole-susceptible isolate (DSY294). These sequential genetic manipulations not only demonstrated that these two resistance mechanisms were those responsible for the development of resistance in DSY296 but also indicated that the quantitative level of resistance as measured in vitro by MIC determinations was a function of the number of genetic resistance mechanisms operating in any strain. The engineered strains were also tested for their responses to fluconazole treatment in a novel 3-day model of invasive C. albicans infection of mice. Fifty percent effective doses (ED(50)s) of fluconazole were highest for DSY296 and decreased proportionally with the sequential removal of each resistance mechanism. However, while the fold differences in ED(50) were proportional to the fold differences in MICs, their magnitude was lower than that measured in vitro and depended on the specific resistance mechanism operating.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20086148      PMCID: PMC2849354          DOI: 10.1128/AAC.01645-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  CIp10, an efficient and convenient integrating vector for Candida albicans.

Authors:  A M Murad; P R Lee; I D Broadbent; C J Barelle; A J Brown
Journal:  Yeast       Date:  2000-03-15       Impact factor: 3.239

2.  EUCAST Technical Note on voriconazole.

Authors: 
Journal:  Clin Microbiol Infect       Date:  2008-10       Impact factor: 8.067

Review 3.  Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation.

Authors:  Dominique Sanglard; Alix Coste; Sélène Ferrari
Journal:  FEMS Yeast Res       Date:  2009-09-07       Impact factor: 2.796

4.  Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients.

Authors:  S Perea; J L López-Ribot; W R Kirkpatrick; R K McAtee; R A Santillán; M Martínez; D Calabrese; D Sanglard; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  Targeted gene disruption in Candida albicans wild-type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates.

Authors:  S Wirsching; S Michel; J Morschhäuser
Journal:  Mol Microbiol       Date:  2000-05       Impact factor: 3.501

6.  Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

Authors:  Sofia Perea; José L López-Ribot; Brian L Wickes; William R Kirkpatrick; Olga P Dib; Stefano P Bachmann; Suzanne M Keller; Marcos Martinez; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus.

Authors:  T M Diaz-Guerra; E Mellado; M Cuenca-Estrella; J L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

8.  Molecular mechanisms of itraconazole resistance in Candida dubliniensis.

Authors:  Emmanuelle Pinjon; Gary P Moran; Colin J Jackson; Steven L Kelly; Dominique Sanglard; David C Coleman; Derek J Sullivan
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

9.  Property differences among the four major Candida albicans strain clades.

Authors:  Donna M MacCallum; Luis Castillo; Kerstin Nather; Carol A Munro; Alistair J P Brown; Neil A R Gow; Frank C Odds
Journal:  Eukaryot Cell       Date:  2009-01-16

10.  Early-expressed chemokines predict kidney immunopathology in experimental disseminated Candida albicans infections.

Authors:  Donna M MacCallum; Luis Castillo; Alistair J P Brown; Neil A R Gow; Frank C Odds
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more
  56 in total

1.  Loss of heterozygosity at an unlinked genomic locus is responsible for the phenotype of a Candida albicans sap4Δ sap5Δ sap6Δ mutant.

Authors:  Nico Dunkel; Joachim Morschhäuser
Journal:  Eukaryot Cell       Date:  2010-11-19

Review 2.  Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

3.  Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infection.

Authors:  Sofia Costa-de-Oliveira; Isabel M Miranda; Ana Silva-Dias; Ana P Silva; Acácio G Rodrigues; Cidália Pina-Vaz
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

Review 4.  Mechanisms of Antifungal Drug Resistance.

Authors:  Leah E Cowen; Dominique Sanglard; Susan J Howard; P David Rogers; David S Perlin
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

5.  Thioredoxin regulates multiple hydrogen peroxide-induced signaling pathways in Candida albicans.

Authors:  Alessandra da Silva Dantas; Miranda J Patterson; Deborah A Smith; Donna M Maccallum; Lars P Erwig; Brian A Morgan; Janet Quinn
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

6.  Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.

Authors:  Dominique Sanglard; Alix T Coste
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

7.  Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo.

Authors:  Keunsook K Lee; Donna M Maccallum; Mette D Jacobsen; Louise A Walker; Frank C Odds; Neil A R Gow; Carol A Munro
Journal:  Antimicrob Agents Chemother       Date:  2011-10-10       Impact factor: 5.191

8.  Relative Contribution of the ABC Transporters Cdr1, Pdh1, and Snq2 to Azole Resistance in Candida glabrata.

Authors:  Sarah G Whaley; Qing Zhang; Kelly E Caudle; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

9.  Multidrug-resistant transporter mdr1p-mediated uptake of a novel antifungal compound.

Authors:  Nuo Sun; Dongmei Li; William Fonzi; Xin Li; Lixin Zhang; Richard Calderone
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

10.  CO(2) acts as a signalling molecule in populations of the fungal pathogen Candida albicans.

Authors:  Rebecca A Hall; Luisa De Sordi; Donna M Maccallum; Hüsnü Topal; Rebecca Eaton; James W Bloor; Gary K Robinson; Lonny R Levin; Jochen Buck; Yue Wang; Neil A R Gow; Clemens Steegborn; Fritz A Mühlschlegel
Journal:  PLoS Pathog       Date:  2010-11-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.